Medigen Vaccine Biologics (ROCO:6547) Stock Based Compensation: NT$39.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
67 GF Score
Price NT$45.60
GF Value NT$57.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Stock Based Compensation?

Medigen Vaccine Biologics ROCO:6547 -0.22% 67 Stock Based Compensation is NT$39.5 Mil as of Mar. 2026. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$57.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Medigen Vaccine Biologics's Stock Based Compensation for the three months ended in Mar. 2026 was NT$9.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$39.5 Mil.

Medigen Vaccine Biologics Stock Based Compensation Related Terms

Medigen Vaccine Biologics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Stock Based Compensation Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.82 75.61 18.31 14.16 31.01

Medigen Vaccine Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 9.97 10.68 9.27 9.58
ROCO:6547
67GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$39.5 Mil.

What does a Stock Based Compensation of NT$39.5 Mil mean?
Medigen Vaccine Biologics (ROCO:6547) has a Stock Based Compensation of NT$39.5 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medigen Vaccine Biologics and its competitors.
Is Medigen Vaccine Biologics' Stock Based Compensation too high?
Medigen Vaccine Biologics' current Stock Based Compensation is NT$39.5 Mil. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Stock Based Compensation compare to VRTX and REGN?
Medigen Vaccine Biologics' Stock Based Compensation of NT$39.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Stock Based Compensation is NT$39.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$57.81, compared to a current price of NT$45.60 — trading 21.1% below its estimated fair value. The current Stock Based Compensation is NT$39.5 Mil. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Stock Based Compensation is NT$39.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued. The current stock price of NT$45.60 is trading 21.1% below its estimated GF Value™ of NT$57.81. GuruFocus considers Medigen Vaccine Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:6547:

  • Stock Based Compensation: NT$39.5 Mil
  • GF Value™: NT$57.81 vs. price of NT$45.60 (21.1% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score

Get the complete analysis for ROCO:6547

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$45.60
Price
NT$57.81
GF Value